AWM
KYNB

Accel Wealth Management’s Kyntra Bio KYNB Stock Holding History

Accel Wealth Management’s Portfolio KYNB Stock Details KYNB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-3,824
Closed -$50.6K – 260
2024
Q4 		$50.6K Hold
3,824
– – 0.02% 250
2024
Q3 		$38.2K Hold
3,824
– – 0.01% 255
2024
Q2 		$85.3K Buy
3,824
+2,066
+118% +$63.8K 0.03% 238
2024
Q1 		$103K Buy
+1,758
New +$75.7K 0.04% 223

Other funds holding KYNB

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Accel Wealth Management's KYNB Position: Q1 2025 in Review

Accel Wealth Management sold out of Kyntra Bio (KYNB) in Q1 2025, closing a stake of 3,824 shares — an estimated $50.6K sold.

Accel Wealth Management first reported a position in KYNB in Q1 2024 and held it in 4 quarters. The position peaked at $103K in Q1 2024. 54 funds tracked by Wall St. Rank hold KYNB as of Q1 2025.

  • Accel Wealth Management reported no remaining Kyntra Bio position as of Q1 2025 after selling out during the quarter.
  • Accel Wealth Management sold 3,824 Kyntra Bio shares in Q1 2025, an estimated $50.6K.
  • Accel Wealth Management first reported a position in Kyntra Bio in Q1 2024 and held it in 4 quarters.
  • Accel Wealth Management's Kyntra Bio position peaked at $103K in Q1 2024.
  • 54 funds tracked by Wall St. Rank held Kyntra Bio as of Q1 2025.

Based on Accel Wealth Management's 13F filing for Q1 2025, filed 10 Apr 2025.